MX2018010824A - Proteinas de union inducibles y metodos de uso. - Google Patents
Proteinas de union inducibles y metodos de uso.Info
- Publication number
- MX2018010824A MX2018010824A MX2018010824A MX2018010824A MX2018010824A MX 2018010824 A MX2018010824 A MX 2018010824A MX 2018010824 A MX2018010824 A MX 2018010824A MX 2018010824 A MX2018010824 A MX 2018010824A MX 2018010824 A MX2018010824 A MX 2018010824A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- polypeptide constructs
- binding proteins
- disclosed
- inducible binding
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a constructor de polipéptido condicionalmente activados que comprenden un dominio de unión a CD3 activado por proteasa, al menos un dominio de extensión de vida útil, y dos o más dominios de unión a uno o más antígenos de objetivo. También se proporcionan composiciones farmacéuticas de los mismos, así como también ácidos nucleicos, vectores de expresión recombinantes y células hospederas para elaborar tales constructos de polipéptido. También se describen métodos para usar los constructos de polipéptido descritos en la prevención, y/o tratamiento de enfermedades, condiciones y trastornos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305092P | 2016-03-08 | 2016-03-08 | |
| PCT/US2017/021435 WO2017156178A1 (en) | 2016-03-08 | 2017-03-08 | Inducible binding proteins and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018010824A true MX2018010824A (es) | 2019-05-15 |
Family
ID=59789722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010824A MX2018010824A (es) | 2016-03-08 | 2017-03-08 | Proteinas de union inducibles y metodos de uso. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180134789A1 (es) |
| EP (1) | EP3426689A4 (es) |
| JP (3) | JP7195927B2 (es) |
| KR (2) | KR102501921B1 (es) |
| CN (1) | CN109071667A (es) |
| AU (1) | AU2017229687A1 (es) |
| BR (1) | BR112018068189A2 (es) |
| CA (1) | CA3016165A1 (es) |
| IL (1) | IL261432B2 (es) |
| MA (1) | MA43816A (es) |
| MX (1) | MX2018010824A (es) |
| SG (1) | SG11201807548SA (es) |
| TW (2) | TW202302631A (es) |
| WO (1) | WO2017156178A1 (es) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2889906T3 (es) | 2015-05-21 | 2022-01-14 | Harpoon Therapeutics Inc | Proteínas de unión triespecíficas y usos médicos |
| EP3377103B2 (en) | 2015-11-19 | 2025-03-12 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CN119060177A (zh) | 2016-05-20 | 2024-12-03 | 哈普恩治疗公司 | 单结构域血清白蛋白结合蛋白质 |
| CN116987189A (zh) | 2016-05-20 | 2023-11-03 | 哈普恩治疗公司 | 单链可变片段cd3结合蛋白质 |
| CN112280796A (zh) | 2016-10-07 | 2021-01-29 | T细胞受体治疗公司 | 使用融合蛋白进行t细胞受体重编程的组合物和方法 |
| MX2019006043A (es) | 2016-11-23 | 2019-09-26 | Harpoon Therapeutics Inc | Proteína de unión de antígeno prostático específico de membrana. |
| AU2017363302A1 (en) | 2016-11-23 | 2019-06-27 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
| EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN |
| WO2018160671A1 (en) * | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Targeted checkpoint inhibitors and methods of use |
| EP3619234A4 (en) * | 2017-05-03 | 2021-05-26 | Harpoon Therapeutics, Inc. | COMPOSITIONS AND PROCEDURES FOR ADOPTIVE CELL THERAPIES |
| SG10202107880XA (en) | 2017-05-12 | 2021-09-29 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
| BR112019023856A2 (pt) | 2017-05-12 | 2020-06-09 | Harpoon Therapeutics Inc | proteínas triespecíficas que visam msln e métodos de utilização |
| JP2020534811A (ja) | 2017-09-08 | 2020-12-03 | マベリック セラピューティクス， インコーポレイテッドＭａｖｅｒｉｃｋ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｆｃ領域を含有する条件的に活性化された結合部分 |
| KR102771251B1 (ko) | 2017-09-08 | 2025-02-24 | 다케다 야쿠힌 고교 가부시키가이샤 | 제약된 조건적으로 활성화된 결합 단백질 |
| BR112020007196A2 (pt) | 2017-10-13 | 2020-12-01 | Harpoon Therapeutics, Inc. | proteínas triespecíficas e métodos de uso |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CN118059232A (zh) * | 2017-11-01 | 2024-05-24 | 南特生物科学公司 | 阻断emt途径并克服癌干细胞的il8 |
| CN110218256B (zh) * | 2018-03-02 | 2020-12-08 | 广西医科大学 | 抗CD3的纳米抗体CD3/Nb29及其制备方法与应用 |
| CN110218253B (zh) * | 2018-03-02 | 2020-12-04 | 广西医科大学 | 抗CD3的纳米抗体CD3/Nb14及其制备方法与应用 |
| SG11202011308VA (en) | 2018-05-14 | 2020-12-30 | Werewolf Therapeutics Inc | Activatable cytokine polypeptides and methods of use thereof |
| CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
| JP2021523192A (ja) * | 2018-05-14 | 2021-09-02 | ハープーン セラピューティクス，インク． | 免疫グロブリン分子の条件的活性化のための結合部分 |
| US20210269530A1 (en) * | 2018-05-14 | 2021-09-02 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| CN120424233A (zh) * | 2018-06-22 | 2025-08-05 | 科优基因公司 | 基于细胞因子的可生物活化药物及其使用方法 |
| WO2020033837A1 (en) | 2018-08-09 | 2020-02-13 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CA3114038A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| JP2022523708A (ja) * | 2019-01-29 | 2022-04-26 | グリットストーン バイオ インコーポレイテッド | 多重特異性結合タンパク質 |
| JP2022524338A (ja) | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | 拘束され、条件的に活性化された結合タンパク質 |
| JP2022524337A (ja) | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | 腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質 |
| US12516128B2 (en) | 2019-05-14 | 2026-01-06 | Harpoon Therapeutics, Inc. | EpCAM binding proteins and methods of use |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| WO2021097060A1 (en) * | 2019-11-13 | 2021-05-20 | Harpoon Therapeutics, Inc. | Pro immune modulating molecule comprising a clustering moiety |
| CN115175926A (zh) | 2019-11-14 | 2022-10-11 | 狼人治疗公司 | 可激活细胞因子多肽及其使用方法 |
| KR20220115611A (ko) * | 2019-12-13 | 2022-08-17 | 큐진 인크. | 사이토카인-기반 생체활성 약물 및 이의 사용 방법 |
| US20230075633A1 (en) * | 2019-12-20 | 2023-03-09 | Shandong Boan Biotechnology Co., Ltd. | Optimized anti-cd3 arm in the generation of t-cell bispecific antibodies for immunotherapy |
| EP4090686A4 (en) * | 2020-01-17 | 2024-03-27 | Immune Targeting Inc. | PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY |
| US20210301015A1 (en) * | 2020-01-17 | 2021-09-30 | Aetio Biotherapy, Inc. | Pro-antibody that reduces off-target toxicity |
| BR112022016550A2 (pt) | 2020-02-21 | 2022-11-16 | Harpoon Therapeutics Inc | Proteínas de ligação a flt3 e métodos de uso |
| KR20220166814A (ko) | 2020-04-09 | 2022-12-19 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 항체를 함유하는 조성물 |
| CN115698072B (zh) | 2020-07-01 | 2023-07-04 | 山东博安生物技术股份有限公司 | 抗gpc3抗体，抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体 |
| WO2022006562A1 (en) | 2020-07-03 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Multispecific coronavirus antibodies |
| PE20230856A1 (es) | 2020-08-17 | 2023-05-29 | Takeda Pharmaceuticals Co | Proteinas de union restringidas activadas de forma condicional |
| CN116157513A (zh) | 2020-08-18 | 2023-05-23 | 昂希莱斯制药公司 | 经修饰的猪胰腺弹性蛋白酶蛋白 |
| CN116261592A (zh) * | 2020-08-18 | 2023-06-13 | 昂希莱斯制药公司 | 经修饰的丝氨酸蛋白酶前蛋白 |
| EP4247850A1 (en) | 2020-11-20 | 2023-09-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
| KR20230135575A (ko) | 2020-12-09 | 2023-09-25 | 재눅스 테라퓨틱스 인크. | Psma 및 이펙터 세포 항원을 표적화하는 종양 활성화항체와 관련된 조성물 및 방법 |
| JP2024513099A (ja) | 2021-04-06 | 2024-03-21 | 武田薬品工業株式会社 | 制約され、条件付きで活性化される結合タンパク質を使用する治療方法 |
| EP4334354A1 (en) | 2021-05-06 | 2024-03-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
| EP4395812A1 (en) | 2021-08-31 | 2024-07-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treatment of autoimmune disorders and cancer |
| EP4436998A1 (en) | 2021-11-24 | 2024-10-02 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
| WO2023114544A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies and uses thereof |
| CA3241407A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Platform for antibody discovery |
| KR20250099103A (ko) | 2022-08-15 | 2025-07-01 | 다나-파버 캔서 인스티튜트 인크. | Cldn4에 대한 항체 및 이의 사용 방법 |
| CN119855829A (zh) | 2022-08-15 | 2025-04-18 | 丹娜-法伯癌症研究院 | 针对msln的抗体及其使用方法 |
| EP4619427A1 (en) * | 2022-11-15 | 2025-09-24 | F. Hoffmann-La Roche AG | Recombinant binding proteins with activatable effector domain |
| WO2025237931A1 (en) * | 2024-05-15 | 2025-11-20 | F. Hoffmann-La Roche Ag | Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004106381A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| US8076459B2 (en) * | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| US20070269422A1 (en) * | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| RU2013110876A (ru) * | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
| US20120225081A1 (en) * | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| HRP20190756T1 (hr) * | 2011-05-21 | 2019-06-14 | Macrogenics, Inc. | Cd3-vezujuće molekule sposobne za vezanje za humani i nehumani cd3 |
| HK1199889A1 (en) * | 2011-07-01 | 2015-07-24 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| NZ627260A (en) * | 2012-02-27 | 2015-10-30 | Boehringer Ingelheim Int | Cx3cr1-binding polypeptides |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| ES2680151T3 (es) * | 2012-03-01 | 2018-09-04 | Amgen Research (Munich) Gmbh | Moléculas de unión de polipéptidos de larga duración |
| US20140004121A1 (en) * | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| CN105431524B (zh) * | 2013-06-10 | 2020-04-21 | 达娜-法勃肿瘤研究所公司 | 用于降低肿瘤细胞的免疫抑制的方法和组合物 |
| MX385936B (es) * | 2014-03-28 | 2025-03-11 | Xencor Inc | Anticuerpos biespecíficos que se unen a cd38 y cd3. |
| EP3377103B2 (en) * | 2015-11-19 | 2025-03-12 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| WO2020033837A1 (en) * | 2018-08-09 | 2020-02-13 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
-
2017
- 2017-03-08 TW TW111119065A patent/TW202302631A/zh unknown
- 2017-03-08 KR KR1020187029014A patent/KR102501921B1/ko active Active
- 2017-03-08 AU AU2017229687A patent/AU2017229687A1/en not_active Abandoned
- 2017-03-08 WO PCT/US2017/021435 patent/WO2017156178A1/en not_active Ceased
- 2017-03-08 IL IL261432A patent/IL261432B2/en unknown
- 2017-03-08 CN CN201780028480.4A patent/CN109071667A/zh active Pending
- 2017-03-08 EP EP17764037.2A patent/EP3426689A4/en active Pending
- 2017-03-08 BR BR112018068189-0A patent/BR112018068189A2/pt active Search and Examination
- 2017-03-08 MA MA043816A patent/MA43816A/fr unknown
- 2017-03-08 JP JP2018547940A patent/JP7195927B2/ja active Active
- 2017-03-08 MX MX2018010824A patent/MX2018010824A/es unknown
- 2017-03-08 TW TW106107861A patent/TW201808990A/zh unknown
- 2017-03-08 SG SG11201807548SA patent/SG11201807548SA/en unknown
- 2017-03-08 CA CA3016165A patent/CA3016165A1/en active Pending
- 2017-03-08 KR KR1020237005284A patent/KR20230041739A/ko not_active Ceased
- 2017-10-06 US US15/727,423 patent/US20180134789A1/en not_active Abandoned
-
2022
- 2022-05-18 JP JP2022081366A patent/JP7293456B2/ja active Active
-
2023
- 2023-06-07 JP JP2023093681A patent/JP2023123519A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230041739A (ko) | 2023-03-24 |
| JP7195927B2 (ja) | 2022-12-26 |
| EP3426689A1 (en) | 2019-01-16 |
| EP3426689A4 (en) | 2020-01-15 |
| BR112018068189A2 (pt) | 2019-02-05 |
| JP7293456B2 (ja) | 2023-06-19 |
| KR20180120245A (ko) | 2018-11-05 |
| JP2019513014A (ja) | 2019-05-23 |
| KR102501921B1 (ko) | 2023-02-21 |
| WO2017156178A1 (en) | 2017-09-14 |
| IL261432B1 (en) | 2023-11-01 |
| IL261432B2 (en) | 2024-03-01 |
| TW202302631A (zh) | 2023-01-16 |
| US20180134789A1 (en) | 2018-05-17 |
| CN109071667A (zh) | 2018-12-21 |
| JP2022140856A (ja) | 2022-09-28 |
| RU2018134949A (ru) | 2020-04-08 |
| MA43816A (fr) | 2018-11-28 |
| CA3016165A1 (en) | 2017-09-14 |
| JP2023123519A (ja) | 2023-09-05 |
| IL261432A (en) | 2018-10-31 |
| AU2017229687A1 (en) | 2018-09-20 |
| SG11201807548SA (en) | 2018-09-27 |
| TW201808990A (zh) | 2018-03-16 |
| RU2018134949A3 (es) | 2020-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| NZ748307A (en) | Gdf15 fusion proteins and uses thereof | |
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| MX2021003554A (es) | Proteinas de union a dll3 y metodos de uso. | |
| ZA202002094B (en) | Trispecific proteins and methods of use | |
| PH12020551907A1 (en) | Antagonizing cd73 antibody | |
| WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
| PH12019500596A1 (en) | Recombinant binding proteins and their use | |
| SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
| PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| MX2019012223A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
| MX2025012685A (es) | Anticuerpos para claudin6 y metodos para tratar el cancer | |
| JOP20220079A1 (ar) | بروتين ربط متعددة الخصوصية لمعالجة السرطان | |
| MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
| MX2024010472A (es) | Polipeptidos que enlazan adamts5, mmp13 y agrecano. | |
| EP4279086A3 (en) | Compositions and methods for treating cancer with anti-cd19 immunotherapy | |
| MY200710A (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| MX2021012047A (es) | Polipeptidos de fusion de serpina y metodos para utilizar los mismos. | |
| PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
| NZ724196A (en) | Uti fusion proteins | |
| ZA202403355B (en) | Single domain antibodies binding to tetanus neurotoxin | |
| WO2016040767A3 (en) | Chrdl-1 epitopes and antibodies | |
| EA201991181A1 (ru) | Psma-нацеленные триспецифические белки и способы их применения |